Husband is on a clinical trial called B7-H3 antibody drug conjulate for stage 4 hormone resistant PCa with...

I understand you're seeking information about your husband's clinical trial and specific genetic markers in prostate cancer. Let me provide some evidence-based information.

According to the NCCN Guidelines for Prostate Cancer (2023 version):

• TP53 and PTEN mutations are considered adverse prognostic factors in prostate cancer
• Genetic testing is recommended for all patients with metastatic prostate cancer to guide treatment decisions
• Clinical trials are considered appropriate options for patients with hormone-resistant (castration-resistant) prostate cancer

The American Society of Clinical Oncology (ASCO) guidelines note that:

• TMPRSS2-ERG fusion is one of the most common genetic alterations in prostate cancer
• B7-H3 (also known as CD276) is emerging as a promising therapeutic target in prostate cancer clinical trials

Regarding B7-H3 antibody-drug conjugates specifically, the National Cancer Institute (NCI) recognizes this as an active area of research for treating aggressive prostate cancers that have become resistant to standard hormonal therapies.

Important points to discuss with your husband's healthcare team:

1. Regular monitoring of PSA levels and imaging
2. Potential side effects specific to the clinical trial drug
3. What other treatment options might be available if needed

Remember that clinical trials are carefully monitored, and your husband's treatment team will be closely tracking his response to therapy. Always report any new symptoms or concerns to the clinical trial team promptly.

Would you like more specific information about any of these aspects of his treatment?